

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA**

IN RE: PROPULSID PRODUCTS : **MDL NO. 1355**
LIABILITY LITIGATION :
: **SECTION: L**
THIS DOCUMENT RELATES TO :
(All Plaintiffs, Enrollees, and Cases in the :
Second MDL Resolution Program) : **JUDGE FALLON**

**DEFENDANTS' MOTION FOR AN ORDER TO TERMINATE THE CLAIMS OF
ALL ENROLLEES IN THE SECOND MDL RESOLUTION PROGRAM AND TO
AUTHORIZE RETURN TO THE DEFENDANTS THE BALANCE OF THE
SETTLEMENT FUND AND ADMINISTRATIVE FUND AFTER ALL
PAYMENTS DUE THEREUNDER HAVE BEEN MADE**

Defendants, Johnson & Johnson and Janssen Pharmaceuticals, Inc. (Defendants), move this Court for entry of an order that terminates the claims of all individuals who enrolled in the Second MDL Resolution Program, as the Program is complete and the claim of every enrollee has been processed, and that returns to the Defendants the balance of the Settlement Fund and Administrative Fund, after all payments due thereunder are paid. In support of their Motion, Defendants submit the attached Memorandum in Support of Defendants' Motion for an Order to Terminate the Claims of All Enrollees in the Second MDL Resolution Program and to Authorize Return to the Defendants the Balance of the Settlement Fund and Administrative Fund After All Payments Due Thereunder Have Been Made.

WHEREFORE, Defendants, Janssen Pharmaceuticals, Inc. and Johnson & Johnson, respectfully request that this Court issue an order terminating the Second MDL Resolution Program including dismissing with prejudice the claims and cases of all the plaintiffs and enrollees therein, including all of the claimants and plaintiffs listed on

Exhibit D to the Quirk Affidavit, and further authorizing the return of balances of the Settlement and Administrative Funds to the Defendants once all payments due under those funds have been made.

Respectfully Submitted:

/s/Brian P. Quirk

JAMES B. IRWIN, T.A. (La. Bar #7172)

BRIAN P. QUIRK (La. Bar #19748)

IRWIN FRITCHIE URQUHART & MOORE LLC

400 Poydras Street, Suite 2700

New Orleans, Louisiana 70130

Phone: (504) 310-2100

Fax: (504) 310-2101

LIAISON COUNSEL FOR DEFENDANTS

JANSSEN PHARMACEUTICALS, INC. AND

JOHNSON & JOHNSON

DRINKER BIDDLE & REATH LLP

THOMAS F. CAMPION

500 Campus Drive

Florham Park, NJ 07932-1047

Phone: (973) 549-7300

Fax: (973) 360-9831

and

DRINKER BIDDLE & REATH LLP

TRACIE MILITANO ROSEN

50 Fremont Street, 20th Floor

San Francisco, CA 94105-2235

Phone: (415) 591-7500

Fax: (415) 591-7510

CO-LEAD COUNSEL FOR DEFENDANTS

JANSSEN PHARMACEUTICALS, INC. AND

JOHNSON & JOHNSON

CERTIFICATE OF SERVICE

I hereby certify that the above and foregoing Defendants' Motion for an Order to Terminate the Claims of All Enrollees in the Second MDL Resolution Program and to Authorize Return to the Defendants the Balance of the Settlement Fund and Administrative Fund After All Payments Due Thereunder Have Been Made, has been served upon all parties by electronically uploading the same to LexisNexis File & Serve, by U.S. mail, certified, return receipt requested to the counsel of record for plaintiffs and claimants, as listed on Exhibit D to the Quirk Affidavit (which has been uploaded to the Court's website, <http://propulsid.laed.uscourts.gov/>), and that the foregoing was electronically filed with the Clerk of Court of the United States District Court for the Eastern District of Louisiana by using the CM/ECF system which will send a Notice of Electronic Filing on this 18th day of September, 2012. This document will also be served on all counsel of record for the enrollees in the Second MDL Resolution Program by Dawn M. Barrios, Esq. of the MDL State Liaison Committee.

/s/Brian P. Quirk

_____ **BRIAN P. QUIRK**

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA**

IN RE: PROPULSID PRODUCTS : **MDL NO. 1355**
LIABILITY LITIGATION :
: **SECTION: L**
THIS DOCUMENT RELATES TO :
(All Plaintiffs, Enrollees, and Cases in the :
Second MDL Resolution Program) : **JUDGE FALLON**

**MEMORANDUM IN SUPPORT OF DEFENDANTS' MOTION FOR AN ORDER
TO TERMINATE THE CLAIMS OF ALL ENROLLEES IN THE SECOND MDL
RESOLUTION PROGRAM AND TO AUTHORIZE RETURN TO THE
DEFENDANTS THE BALANCE OF THE SETTLEMENT FUND AND
ADMINISTRATIVE FUND AFTER ALL
PAYMENTS DUE THEREUNDER HAVE BEEN MADE**

Defendants, Johnson & Johnson and Janssen Pharmaceuticals, Inc. (Defendants), submit the following Memorandum in Support of Defendants' Motion for an Order to Terminate the Claims of All Enrollees in the Second MDL Resolution Program and to Authorize Return to the Defendants the Balance of the Settlement Fund and Administrative Fund After All Payments Due Thereunder Have Been Made.

1. In December 2005, the Plaintiffs' Steering Committee (PSC), the State Liaison Committee (SLC), and Defendants reached an agreement to create a comprehensive resolution program (Second MDL Resolution Program) to resolve the state and federal lawsuits that were not eligible to enroll, or chose not to enroll, in the First MDL Resolution Program, as well as the remaining unfiled claims subject to tolling agreements.

2. The Second MDL Resolution Program became effective on October 31, 2006, when 90% of the plaintiffs representing decedents, 95% of the personal injury

plaintiffs and most of the remaining tolled claimants were confirmed enrolled and had agreed to the terms of the program.

3. Enrollment in the Second MDL Resolution Program closed on December 7, 2007, and the deadline for filing claim forms expired in April 2008.

4. The terms of the Second MDL Resolution Program are set forth in the December 19, 2005 Consent Order and in the Second MDL Resolution Program Term Sheet, dated December 15, 2005. Copies of these documents are attached as Exhibits A and B, respectively, to the Affidavit of Brian P. Quirk, Esq., counsel for Defendants (Quirk Affidavit). The Quirk Affidavit is filed concurrently with this Motion. These documents were made a part of the enrollment form, and those who enrolled in the Second MDL Resolution Program certified that they had read and understood these documents.

5. Those who enrolled in the Second MDL Resolution Program filled out an enrollment form and agreed to its terms. A copy of the enrollment form is attached as Exhibit C to the Quirk Affidavit. Upon enrolling, enrollees agreed that they would be subject to the jurisdiction of the MDL Court, could not withdraw from the Second MDL Resolution Program, would be bound by the Program's results and would surrender any other rights or claims they may have had with respect to Propulsid® use. They further agreed that their enrollment served as a release of any claims against the Defendants and any other parties against whom they may have had a claim. Upon enrollment, they further agreed that their claims would be dismissed if they failed to serve completed claim forms and provide the required medical records within the timeframes specified.

6. The Term Sheet states that “[t]his Program will be in lieu of any further litigation by the plaintiffs and tolling agreement claimants who enrolled in this Second MDL Program respecting their acquisition or use of Propulsid.” See Exhibit B to the Quirk Affidavit at page 2. It further sets forth that the parties will jointly petition the MDL Court to accept jurisdiction over this Program and to manage the resolution of both federal and state court actions, as well as claims of claimants. On December 19, 2005, this Court signed the parties’ Consent Order, assuming jurisdiction over enrolled state plaintiffs and over claimants, who would not otherwise be subject to the jurisdiction of the MDL Court. See Exhibit A to the Quirk Affidavit, ¶ 2.

7. All plaintiffs who enrolled in the Second MDL Resolution Program, including plaintiffs whose cases were pending in state courts, were required to deliver to defense counsel a fully-executed stipulation of dismissal and proposed order of dismissal with prejudice of their cases. These stipulations of dismissal were styled with the MDL Court’s caption and the MDL Case/Docket number. See Exhibit C to the Quirk Affidavit.

8. As part of their enrollment packages, enrollees were instructed to fill out claim forms and to submit claim forms and medical records to the Special Master’s Office within certain deadlines. The Court additionally posted all forms and information related to the Second MDL Resolution Program on its website. The Special Master’s Office collected and tracked the receipt of the enrollees’ forms and sent to their counsel notices of delinquent and/or deficient submissions, as appropriate. The Special Master’s Office additionally notified counsel for all enrollees of the enrollment status of each enrollee (whether each had been disqualified and the reason(s) for that determination, with the

opportunity to challenge that disqualification or seek reconsideration of same, whether each had been qualified and how each had been qualified – whether as a wrongful death plaintiff, a personal injury plaintiff or a tolling claimant). The Special Master’s Office regularly shared with the parties data updates regarding enrollment and the receipt of claim forms and medical records from enrollees. See Juneau Affidavit filed concurrently with this Motion, ¶ 2.

9. As the Special Master’s Office received submissions from enrollees and deemed them complete for review, it forwarded the claim forms and medical records to a three-physician panel for review and eligibility determinations. For the remaining balance of submissions that were not deemed eligible for awards, claimants with sufficient records were entitled to payments to defray the costs of obtaining medical records required for participation in the Program (medical records reimbursements) in accordance with the Term Sheet. The Special Master’s Office processed and paid medical records reimbursements to a large number of enrollees in the Second MDL Resolution Program. All enrollees who received awards or medical records reimbursements have had their claims fully processed, and their claims and cases should be terminated. See Juneau Affidavit, ¶ 3.

10. Some enrollees failed to submit claim forms. Some enrollees failed to submit medical records. Some enrollees failed to submit the necessary records to qualify them for medical records reimbursements. Each was given notice of these deficiencies, with the ability to cure them, and their claims were fully processed according to the

requirements of the Term Sheet for the Second MDL Resolution Program. Their cases and claims should be terminated. See Juneau Affidavit, ¶ 4.

11. A list of every enrollee and plaintiff in the Second MDL Resolution Program is attached as Exhibit D to the Quirk Affidavit and can be found on the Court's website at <http://propulsid.laed.uscourts.gov/>.

12. All claims have been processed and finalized, and the Defendants seek an order from this Court, terminating the Second MDL Resolution Program and the claims and cases of all enrollees in the Second MDL Resolution Program, and authorizing the Special Master to return to the Defendants the balance of the money in the Administrative Fund and Settlement Fund once all the payments that are due under those Funds have been paid.

Accordingly, Defendants, Janssen Pharmaceuticals, Inc. and Johnson & Johnson, respectfully request that this Court issue an order terminating the Second MDL Resolution Program including dismissing with prejudice the claims and cases of all the plaintiffs and enrollees therein, including all of the claimants and plaintiffs listed on Exhibit D to the Quirk Affidavit, and further authorizing the return of balances of the Settlement and Administrative Funds to the Defendants once all payments due under those funds have been made.

Respectfully Submitted:

/s/Brian P. Quirk

JAMES B. IRWIN, T.A. (La. Bar #7172)

BRIAN P. QUIRK (La. Bar #19748)

IRWIN FRITCHIE URQUHART & MOORE LLC

400 Poydras Street, Suite 2700

New Orleans, Louisiana 70130

Phone: (504) 310-2100

Fax: (504) 310-2101

**LIAISON COUNSEL FOR DEFENDANTS
JANSSEN PHARMACEUTICALS, INC. AND
JOHNSON & JOHNSON**

DRINKER BIDDLE & REATH LLP

THOMAS F. CAMPION

500 Campus Drive

Florham Park, NJ 07932-1047

Phone: (973) 549-7300

Fax: (973) 360-9831

and

DRINKER BIDDLE & REATH LLP

TRACIE MILITANO ROSEN

50 Fremont Street, 20th Floor

San Francisco, CA 94105-2235

Phone: (415) 591-7500

Fax: (415) 591-7510

**CO-LEAD COUNSEL FOR DEFENDANTS
JANSSEN PHARMACEUTICALS, INC. AND
JOHNSON & JOHNSON**

CERTIFICATE OF SERVICE

I hereby certify that the above and foregoing Defendants' Memorandum in Support of Motion for an Order to Terminate the Claims of All Enrollees in the Second MDL Resolution Program and to Authorize Return to the Defendants the Balance of the Settlement Fund and Administrative Fund After All Payments Due Thereunder Have Been Made, has been served upon all parties by electronically uploading the same to LexisNexis File & Serve, by U.S. mail, certified, return receipt requested to the counsel of record for plaintiffs and claimants, as listed on Exhibit D to the Quirk Affidavit (which has been uploaded to the Court's website, <http://propulsid.laed.uscourts.gov/>), and that the foregoing was electronically filed with the Clerk of Court of the United States District Court for the Eastern District of Louisiana by using the CM/ECF system which will send a Notice of Electronic Filing on this 18th day of September, 2012. This document will also be served on all counsel of record for the enrollees in the Second MDL Resolution Program by Dawn M. Barrios, Esq. of the MDL State Liaison Committee.

/s/Brian P. Quirk

BRIAN P. QUIRK

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA**

IN RE: PROPULSID PRODUCTS : **MDL NO. 1355**
LIABILITY LITIGATION :
: **SECTION: L**
THIS DOCUMENT RELATES TO :
(All Plaintiffs, Enrollees, and Cases in the :
Second MDL Resolution Program) : **JUDGE FALLON**

**AFFIDAVIT OF BRIAN P. QUIRK IN SUPPORT OF
DEFENDANTS' MOTION FOR AN ORDER TO TERMINATE THE CLAIMS OF
ALL ENROLLEES IN THE SECOND MDL RESOLUTION PROGRAM AND TO
AUTHORIZE RETURN TO THE DEFENDANTS THE BALANCE OF THE
SETTLEMENT FUND AND ADMINISTRATIVE FUND AFTER ALL
PAYMENTS DUE THEREUNDER HAVE BEEN MADE**

STATE OF LOUISIANA

PARISH OF ORLEANS

Brian P. Quirk, having been duly sworn according to his oath, deposes and says:

1. I am counsel with the law firm of Irwin Fritchie Urquhart & Moore LLC, attorneys for Defendants in this action. Based on my responsibilities, I am familiar with my firm's records as they relate to this litigation and if called as a witness, could and would testify to matters as set forth below.

2. Attached hereto as Exhibit A is a true and correct copy of the December 19, 2005 Consent Order for the Second MDL Resolution Program.

3. Attached hereto as Exhibit B is a true and correct copy of Term Sheet for the Second MDL Resolution Program.

4. Attached hereto as Exhibit C is a true and correct copy of the Enrollment and Stipulations of Dismissal with Prejudice Forms for the Second MDL Resolution Program.


5. Attached hereto as Exhibit D is a true and correct copy of the Propulsid Settlement Enrollments, specifically a listing of all persons, and their applicable counsel and case caption, who enrolled in the Second MDL Resolution Program. This listing is in alphabetical order, 293 pages long, and is retrievable on the court's website for this litigation, at <http://propulsid.laed.uscourts.gov/>, as well as on the Court's Pacer System and LexisNexis File and Serve.

I declare that the foregoing is true and correct.



BRIAN P. QUIRK

Sworn to before me and subscribed
in my presence this 17th day of
September, 2012.



Notary Public
Name Printed: Kelly Juneau
La. Bar No. 30573

KELLY G. JUNEAU
NOTARY PUBLIC
State of Louisiana
LA Bar Roll No. 30573
My Commission is issued for Life.

THIS IS PAGE 33 OF 37 - PLEASE READ ALL PAGES

COPY IN CHAMBERS

FILED
U.S. DISTRICT COURT
EASTERN DISTRICT OF LA
2005 DEC 20 PM 3:01
LORLETTA G. WHYTE
CLERK

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA


-----	:	MDL NO. 1355
IN RE: PROPULSID	:	
	:	SECTION "L"
PRODUCTS LIABILITY LITIGATION	:	
	:	JUDGE FALLON
-----	:	

THIS DOCUMENT RELATES TO ALL CASES

CONSENT ORDER

The Plaintiffs' Steering Committee (PSC), The State Liaison Committee (SLC) and the defendants Janssen, L.P., formerly known as Janssen Pharmaceutica Inc. and Johnson & Johnson (hereafter "the Parties") have negotiated a comprehensive resolution program (hereafter the "Second MDL Program") to conclude as many cases as possible in both state and federal courts which are pending as of this date, as well as claims covered under tolling agreements. A copy of the Second MDL Program (MDL 1355) Term Sheet is attached. The Second MDL Program tracks the provisions of the First MDL Program's Term Sheet which is attached to this Court's Order of February 4, 2004. The Second MDL Program covers federal court and state court plaintiffs and tolling agreement claimants in Propulsid matters who were not eligible to enroll in The First MDL Program or who chose not to enroll in it.

_____	Fee	_____
_____	Process	_____
<input checked="" type="checkbox"/>	Dktd	_____
_____	ClRmDep	_____
_____	Doc. No	_____



THIS IS PAGE 34 OF 37 - PLEASE READ ALL PAGES

This Program will come into existence when an agreed upon number of plaintiffs and an agreed upon number of persons who have signed tolling agreements consent to enroll in the Second MDL Program and to be bound by its terms. Upon enrollment in the Second MDL Program, any enrolled plaintiff or claimant thereby consents to the terms and conditions of the Second MDL Program and accepts the jurisdiction of the MDL Court until all proceedings under the Second MDL Program have been concluded and agrees that this MDL Court, by their consent, is empowered to enter orders (1) terminating plaintiff and claimant rights to sue defendants if they fail to submit the medical records within the time set forth in the attached Term Sheet or any approved extension thereof or if the Medical Panel decides that they are not entitled to compensation and (2) authorizing the Special Master to pay from the Settlement Fund any award that he makes in favor of a plaintiff or claimant consistent with this Program in return for a release of all claims.

Because the Second MDL Program is private, its terms do not require approval of this MDL Court except as may be necessary in the approval of any settlement involving minors or incompetents or a determination of appropriate attorneys' fees as set forth in Section 19 of the attached Term Sheet. Notwithstanding, the Parties have petitioned this MDL Court for its participation and assistance in certain areas respecting management of the Second MDL Program once the minimum enrollment levels required to activate the Program are achieved. The Parties have represented that the Second MDL Program has, as one of its conditions, the requirement that this MDL Court agree to participate in the following aspects of the Program:

1. Acceptance of jurisdiction over enrolled plaintiffs and enrolled claimants in the Second MDL Program and defendants until all proceedings under the Second MDL Program have been concluded, with empowerment to enter orders (i) terminating plaintiff and claimant

THIS IS PAGE 35 OF 37 - PLEASE READ ALL PAGES

rights to sue defendants if they fail to submit the medical records within the time set forth in the Term Sheet or any approved extension thereof or if the Medical Panel decides that they are not entitled to compensation and (2) authorizing the Special Master to pay from the Settlement Fund any award that he makes in favor of a plaintiff or claimant consistent with this Second MDL Program in return for a release of all claims.

2. Appointment of a Special Master to manage the Second MDL Program in accordance with the terms agreed upon by the Parties;

3. Replacement of the Special Master or any physician appointed to the Medical Panel as necessary and appropriate;

4. Maintenance as open cases on any state court or federal court docket, all lawsuits whose plaintiffs enter this Program, to be dismissed with prejudice only upon payment of an award under this Program or upon determination by the Medical Panel established under this Program that the claimant is not eligible for an award under the Program;

5. The MDL Court will determine and approve an appropriate award of attorneys' fees to the PSC and SLC, such fee to be paid by defendants in an amount not to exceed the amount stipulated under the Term Sheet; and

6. Exercise of such additional powers as may be called for under the Program or as may be necessary for the proper management of cases which are before this Court pursuant to its appointment as the MDL Court for this Propulsid litigation.

THIS IS PAGE 36 OF 37 - PLEASE READ ALL PAGES

UPON CONSIDERING THE ABOVE, IT IS ORDERED AS FOLLOWS:

1. If the minimum enrollment required under the Second MDL Program is achieved, this MDL Court agrees to exercise the powers which the parties have requested of it in that Program;
2. This MDL Court, by consent of the parties and upon the Second MDL Program becoming effective, shall assume jurisdiction over enrolled plaintiffs, enrolled claimants not presently subject to the jurisdiction of the MDL Court and defendants until all proceedings under the Second MDL Program have been concluded and will exercise its powers (1) to terminate plaintiff and claimant rights to sue defendants if they fail to submit the medical records within the time set forth in the Term Sheet or any approved extension thereof or if the Medical Panel decides that they are not entitled to compensation and (2) to authorize the Special Master to pay from the Settlement Fund any award that he makes in favor of a plaintiff or claimant consistent with this Second MDL Program in return for a release of all claims;
3. Patrick A. Juneau is appointed Special Master of the Second MDL Program, to exercise his rights and responsibilities as set forth in the Program. His appointment will become effective as soon as the minimum enrollment under the Program has been achieved;
4. After the Second MDL Program has become effective, upon application by the Plaintiffs' Steering Committee (PSC) and the State Liaison Committee (SLC), this Court will set a hearing for the determination of an appropriate award of attorneys' fees to the PSC and SLC to be paid by defendants subject to the provisions and limitations of the Term Sheet;

THIS IS PAGE 37 OF 37 - PLEASE READ ALL PAGES

5. The Enrollment Form and Claim Forms, including the Short Form Medical Records Reimbursement Form, used in the First MDL Program are approved for use in the Second MDL Program provided they are appropriately entitled as Second MDL Program forms;

6. The parties agree that the procedure established respecting management of the First MDL Program pursuant to Section 6 of this Court's February 4, 2004 Order shall, to the greatest extent possible, be the procedures which shall control management of the Second MDL Program.

7. This Court will issue additional orders as may be called for or appropriate with respect to the Second MDL Program or as may be necessary for this Propulsid litigation.

NEW ORLEANS, LOUISIANA, this 19 day of December, 2005.



JUDGE ELDON E. FALLON

THIS IS PAGE 12 OF 37 - PLEASE READ ALL PAGES

SECOND MDL PROGRAM

TERM SHEET

In February 2004 the Plaintiffs' Steering Committee and defense counsel in the suit entitled In Re: Propulsid Products Liability Litigation, United States District Court, Eastern District of Louisiana, MDL No. 1355 (hereafter "the MDL Court" or the "MDL Litigation") entered into a written agreement (hereafter "the MDL Term Sheet") whereby they established a global mediation and resolution program (hereafter the "First MDL Program"). The MDL Court thereupon entered a Consent Order on February 4, 2004 which, among other things, accepted jurisdiction over the plaintiffs and tolling agreement claimants enrolled in the First MDL Program and appointed a Special Master to exercise the rights and responsibilities set forth in the First MDL Program.

The PSC and defense counsel thereafter amended the MDL Term Sheet. The First MDL Program is now functioning pursuant to the aforesaid Consent Order and amended MDL Term Sheet.

The First MDL Program does not provide for participation by plaintiffs in state court cases where their Complaints seek damages respecting their use of Propulsid. Nor does it provide for participation by plaintiffs in cases filed in or removed to federal courts after February 1, 2004.


The PSC and SLC have received requests from counsel representing substantial numbers of plaintiffs in cases pending in state courts seeking their clients' inclusion in the First MDL Program or some version of it. The PSC and defense counsel have consulted about those inquiries. They have agreed that, in view of the extensive negotiations and effort which went into establishing the First MDL Program, it would be desirable to establish a second mediation and resolution program for the state court cases which shall be administered as an offshoot of the First MDL Program. In reaching this conclusion, they have consulted with the State Liaison Committee ("SLC") previously established by the MDL Court. This new program will be known as the "Second MDL Program." The PSC, SLC and defense counsel believe that the most effective way of resolving the claims of: (a) state court plaintiffs, (b) federal court plaintiffs who were eligible to enroll in the First MDL Program but did not do so, (c) those federal court plaintiffs (including Achord plaintiffs) whose suits were filed after February 1, 2004 and who thus were not eligible to participate in the First MDL program and (d) persons under tolling agreements who did not enroll in the First MDL Program but who may now wish to enroll, is to establish the program set forth in this Term Sheet and to bring the program and those claims under the jurisdiction of the MDL Court.

The PSC and the State Liaison Committee ("SLC") have committed to making a substantial effort to enroll in this new program the required number of state court plaintiffs and persons under tolling agreements who did not elect or were not eligible to join the First MDL Program. There are approximately 550 plaintiffs ("plaintiffs" as defined in Section 1(B) of this Term Sheet) maintaining suits in various state courts.

In addition to the plaintiffs in state court suits, there are approximately 1544 (inclusive of Achord plaintiffs) plaintiffs ("plaintiffs" as defined in section 1(B) of this Term Sheet) in federal court

SF1A365795M

THIS IS PAGE 12 OF 37 - PLEASE READ ALL PAGES



THIS IS PAGE 13 OF 37 - PLEASE READ ALL PAGES

actions whose suits were not pending as of February 1, 2004, thus rendering them ineligible to participate in the First MDL Program. They will be eligible to enroll in the Second Program. This Second MDL Program is an entirely voluntary one. No plaintiff or claimant is required to enter it but those who do enter it will be bound by its terms. As with the First MDL Program, entrance into the Second MDL Program will terminate any state or federal court litigation brought by those persons and will preclude those who are under tolling agreements from ever commencing any such litigation.

This document reflects the agreement which the PSC, the SLC and defense counsel have reached.

1. THE PROGRAM

A. The PSC, SLC and the defendants will establish a second global mediation and resolution program (hereafter the "Second MDL Program") whose purpose is to establish a system, subject to the jurisdiction of the MDL Court, whereby the claims of state court plaintiffs, certain plaintiffs in federal court suits and persons under tolling agreements will be reviewed and resolved by the panel of physicians who will be determining eligibility for payments in the "Propulsid MDL 1355 Settlement Program" (hereafter the "First MDL Program"). The Second MDL Program will be posted on the MDL Court's website.

This Program will be in lieu of any further litigation by the plaintiffs and tolling agreement claimants who enroll in this Second MDL Program respecting their acquisition or use of Propulsid.

The defendants are satisfied that the most effective and efficient way of managing the resolution of state court actions and the suits and claims of the other plaintiffs and claimants identified herein is to establish the Second MDL Program under the jurisdiction of the MDL Court which already has jurisdiction over the First MDL Program. In order for this to occur, the MDL Court will have to decide whether it chooses to exercise its jurisdiction over this matter. The PSC, SLC and the defendants will therefore jointly petition the MDL Court to accept jurisdiction on the same or similar terms found in the Consent Order of February 4, 2004. If the petition is not granted, then the agreement set forth in this Term Sheet shall terminate and become null and void.

The attorneys for the plaintiffs in the state court matters shall be given notice of the petition and shall have the right to submit their position on the same in writing and to appear before the MDL Court when the application is heard. The Second MDL Program, as noted in this Term Sheet, is entirely voluntary.

B. The Second MDL Program will not become effective unless and until (1) 90% of the plaintiffs who are maintaining wrongful death actions as of November 15, 2005 in state court cases and in federal court cases (excluding Achord cases) filed after February 1, 2004, (2) 95% of the plaintiffs who are maintaining other than wrongful death actions as of November 15, 2005 in state court cases and in federal court cases (excluding Achord cases) filed after February 1, 2004, (3) 100% of the represented Achord plaintiffs whose suits were not pending as of February

THIS IS PAGE 14 OF 37 - PLEASE READ ALL PAGES

1, 2004 and (4) 5,000 of the tolling agreement claimants who did not enroll in the First MDL Program have agreed in writing by completion and service of the Enrollment Form (attached as Exhibit B) to become part of the Second MDL Court Program and to be bound by its terms. To be counted towards these enrollment minimums and to participate in this Program, plaintiffs and claimants under tolling agreements must be citizens or residents of the United States.

These four components noted in Section 1(B) shall be known as the "minimum enrollment." At the present time there are approximately 125 wrongful death actions and 1944 other than wrongful death actions pending in groups (1) and (2) above. "Pending" shall mean cases filed in any state or federal court in the United States by November 15, 2005. Plaintiffs and claimants are limited to citizens or residents of the United States. Defendants have previously supplied the PSC and SLC with relevant information about the persons in groups (1), (2), (3) and (4) and the identity of their counsel.

"Plaintiffs" in this Agreement means all persons who claim a loss as a result of the death or injury claimed to have resulted from use of Propulsid. Thus spouses qualify as one plaintiff; all persons who claim any loss as a result of the death or injury of a person qualify as one plaintiff. Thus, spouses, children and/or heirs, together with the person who sustained the claimed injury or death, constitute a single plaintiff for purposes of Section 1.

Once the minimum enrollment requirements described above and in Section 21 have been reached, the Second MDL Program enrollment shall remain open for six additional months. As the percentages of plaintiffs who enroll during this additional six-month period reach the levels beyond the enrollment percentages described in this Section, the settlement fund shall be increased in accordance with the terms of Section 3(B). The parties reserve the right to agree to extend this additional period beyond the six months.

C. The agreements described herein shall be signed by counsel for the plaintiffs or claimants who shall represent that they have full authority from their clients to enter into the agreement.

D. The Second MDL Program will be established pursuant to an order of the MDL Court. It will be administered by the Special Master appointed by the MDL Court pursuant to Federal Rule of Civil Procedure 53. The Special Master shall have the authority to engage support personnel to assist in management of the Program and shall be required to render reports to the MDL court from time to time respecting the management of the Second MDL Program, including allowance and disallowance of claims.

E. The terms, conditions and qualifications of the Second MDL Program are set forth in the First MDL Program attached hereto as Exhibit A.

F. All plaintiffs and claimants who enroll in this Second MDL Program, and their attorneys, thereby agree to submit themselves to the jurisdiction of the MDL Court over that Program for all purposes.

THIS IS PAGE 15 OF 37 - PLEASE READ ALL PAGES

G. Notwithstanding any other provision of this Term Sheet, no plaintiffs or claimants shall be entitled to or allowed to enroll in this Second MDL Program if their lawsuits had not been filed by November 15, 2005 or their tolling agreements had not been signed by the defendants by November 15, 2005. Nor will any plaintiffs or claimants be entitled to or allowed to enroll in this Second MDL Program if they enrolled in the First MDL Program. No person who enrolled in the First MDL Program may enroll in the Second MDL Program. However, any person who was eligible to enroll in the First MDL Program but did not do so may enroll in the Second MDL Program.

2. SPECIAL MASTER AND MEDICAL PANEL

A. Eligibility for payment will be based on medical records, as is set forth in more detail in the Program.

B. The Medical Panel described herein shall have the sole and exclusive authority to determine eligibility for payment under the Second MDL Program or non-eligibility under the Second MDL Program.

C. Once the Medical Panel has made a determination that a plaintiff or claimant is eligible for payment and has determined the category in which the plaintiff or claimant falls, the Special Master shall have sole and exclusive authority to determine the sum to be awarded to that person.

D. The determinations made by the Medical Panel and the Special Master are final determinations and, other than as set forth in Louisiana Civil Code Article 1953, shall not be subject to review or appeal, whether by mandamus or otherwise, in any court by the plaintiffs, the claimants or the defendants.

3. SETTLEMENT AND ADMINISTRATIVE FUNDS

A. The parties agree that the defendants shall pay the sums designated below for the settlement and administrative funds and for the payment described in Section 19.

B. The settlement fund shall be funded by the defendants and shall be no less than \$14,500,000.00 and no more than \$15,000,000.00. The fund shall be \$14,500,000.00 if 90% of the state court and federal court plaintiffs described in Section 1(B) who are maintaining death cases, 95% of the state court and federal court plaintiffs described in Section 1(B) who are maintaining non-death cases, 100% of the represented Achord plaintiffs described in Section 1(B) and the 5,000 persons described in Section 1(B) agree in writing through their counsel to enter into the agreement, all as set forth in Section 1(D).

In the event more than 90% of the death case plaintiffs, as defined in Section 1, agree in writing through their counsel to enter into the agreement set forth in Section 1(D), then the settlement fund shall be increased by an additional sum as follows:

Percentage enrolling	Additional sum to be paid to settlement fund
91%	\$25,333.00

THIS IS PAGE 15 OF 37 - PLEASE READ ALL PAGES

THIS IS PAGE 16 OF 37 - PLEASE READ ALL PAGES

92%	\$25,333.00
93%	\$25,333.00
94%	\$34,455.00
95%	\$34,455.00
96%	\$34,455.00
97%	\$50,159.00
98%	\$50,159.00
99%	\$50,159.00
100%	\$50,159.00

Accordingly, if there is 100% enrollment of the death case plaintiffs, the additional sum to be paid to the settlement fund will total \$380,000.00.

In the event more than 95% of the non-death case plaintiffs, as defined in Section 1(B) agree in writing through their counsel to enter into the agreement set forth in Section 1D, then the settlement fund shall be increased by an additional sum as follows:

Percentage enrolling	Additional sum to be paid to settlement fund
96%	\$7,500.00
97%	\$7,500.00
98%	\$15,000.00
99%	\$30,000.00
100%	\$60,000.00

Accordingly, if there is a 100% enrollment of these non-death case plaintiffs, the additional sum to be paid to the settlement fund will total \$120,000.00.

There shall be no pro rata increased payment to the Settlement Fund if the number of plaintiffs who agree in writing through their counsel to enter into the agreement are greater than any of the above described levels. The increased payment is only due if the actual level is reached.

C. The parties have evaluated the expected costs of the administrative fund, discussed them with each other and have anticipated that the costs will not exceed \$3,000,000.00. The defendants have, nevertheless, agreed to fund the administrative fund in the amount of \$3,000,000.00. In the unlikely event it appears during the administration of the Second MDL Program that the costs of the administrative fund might exceed \$3,000,000.00, either party shall bring the matter to the attention of the MDL Court, which shall have the authority to modify the Second MDL Program to ensure that the administrative fund does not exceed \$3,000,000.00. Under no circumstances shall the defendants have any obligation to pay more than \$3,000,000.00 for the administrative fund. Any unused portion of the Administrative fund shall be returned to defendants.

D. Counsel for plaintiffs described in Section 1(B) shall not be permitted to enroll less than 100% of the plaintiffs they represent in state and federal court cases and persons they represent

THIS IS PAGE 16 OF 37 - PLEASE READ ALL PAGES

THIS IS PAGE 17 OF 37 - PLEASE READ ALL PAGES

under tolling agreements. Counsel for plaintiffs within the meaning of this Section are defined to be those who were counsel of record per pleadings filed before November 15, 2005.

E. The parties wish to have the settlement fund maintained in as secure a manner as possible so that those funds will be available to be paid to the plaintiffs and claimants who qualify for payment. They will consult as to the bank depository or other prudential financial institution which will be chosen to hold those funds and will also consult as to the form of prudent investment vehicles to be used for investment of the funds. The PSC and SLC shall designate the institution subject to defendants' agreement. Once a tentative decision as to the institution and the form of the investment has been made, the parties shall apply to the Court for approval of the same as having been prudent decisions. The institution so chosen shall thereupon consent to the jurisdiction of the MDL Court acknowledging that it alone has the obligation to manage the settlement fund. Periodic reports should be made to the Court of the interest earned, distributions made, and other matters involving the status of administration. Its management shall thereafter be subject to review by the MDL Court.

F. The defendants will make the initial payment into the settlement fund within 30 days of confirmation that the enrollment levels (90% of the death plaintiffs, 95% of the non-death plaintiffs, 100% of the represented Achord plaintiffs and 5000 of the remaining tolling agreement claimants as described in Section I(B)) have been reached. Thereafter, defendants will pay the additional sums set forth in 3B into the settlement fund within 30 days of confirmation for each 1% incremental increase in death and/or non-death enrollees. If, upon completion of the Second MDL Court Program, the aggregate sum of the awards of the Special Master is less than the settlement fund, the difference and interest on that difference shall be returned to the defendants.

4. WAIVERS AND RELEASES

A. In consideration for the plaintiffs and claimants agreeing to enter the Second MDL Program and surrendering their rights to litigate their cases or claims, the defendants unconditionally waive all defenses in law and equity which they have or may have to those cases or claims except as otherwise described in this document.

B. In consideration for the defendants waiving the defenses they have in law and equity and agreeing to enter the Second MDL Program, the plaintiffs and claimants unconditionally release whatever rights they have or may have against the defendants, their agents, servants, employees, officers and directors and all health care professionals, health care providers, health care facilities, pharmacies and other distributors of Propulsid®, and all of these individuals' and entities' parents and subsidiaries, affiliates, agents, attorneys, servants, employees, officers and directors and those who acted in concert with them together with their respective insurers. In addition, no plaintiff shall enter the Second MDL Program until his or her counsel shall have executed a stipulation of dismissal of the entire action with prejudice and claimants shall enter the Second MDL Program with the understanding that their claims will be subject to an order of termination once the processing of their claims has been finalized. The same shall be given to counsel for the defendants who are to hold it in escrow and who are authorized to file it only upon the determination by the Medical Panel that the claim does not qualify for payment or upon

THIS IS PAGE 18 OF 37 - PLEASE READ ALL PAGES

confirmation by the Special Master that the claim has been dismissed under Section 7 or, if the claim is held by the Medical Panel to qualify for payment, only upon payment of the award.

C. By entering the Second MDL Program, the plaintiffs, claimants and defendants acknowledge that decisions to be made by the Medical Panel and Special Master may be ones with which they disagree. They further acknowledge that this eventuality is part of the Second MDL Program and they accept it.

D. All releases from plaintiffs or claimants given under this Program shall be given to Janssen, L.P (formerly known as Janssen Pharmaceutica Inc.) Johnson & Johnson, Janssen Research Foundation, Janssen Pharmaceutica, N.V., Robert Wood Johnson Pharmaceutical Research Institute, and all entities and persons related to them and all health care professionals, health care providers, health care facilities, pharmacies and other distributors of Propulsid®, and all of these individuals' and entities' parents and subsidiaries, affiliates, agents, attorneys, servants, employees, officers and directors and those who may have acted in concert with them, together with their respective insurers, and serves as a waiver of California Civil Code Section 1542, if applicable, which provides that, "a general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor."

5. MEDICAL RECORDS SUBMISSIONS.

A. The parties shall submit with the Consent Order the Enrollment and Claim Forms attached as Exhibits B and C. The Special Master shall make those forms available to those persons who elect to join the Second MDL Program and, once completed, to the parties, and shall determine whether the completed forms adequately provide the information required under the Second MDL Program. The forms will also be available on the Court's website.

B. The attorneys representing the plaintiffs and the attorneys representing the claimants shall have the right to collect and submit the medical records called for by the Second MDL Program through their own efforts. They shall also have the right to use any common medical records collecting service which may be established for purposes of collecting the medical records and submitting them to the Medical Panel. The defendants reserve the right to submit medical records which they have gathered on plaintiffs and claimants and to examine the medical records submitted on their behalf. The attorneys representing the plaintiffs and the attorneys representing the claimants also have the right to examine the medical records submitted by the defendants. All parties have the right to argue to the Special Master whether the Medical Records Submission has been accomplished in accordance with the requirements of the Second MDL Program. All records of claimants who opt in which were at any time collected or to be collected by claimants and/or defendants shall be promptly placed in the depository. Claimants and defendants, by placing their records in the depository, consent to review of such records, including medical records, by parties' attorneys, medical experts, consultants, depository staff, the Medical Panel, the Court and the Special Master, but such records shall otherwise remain confidential in conformity with HIPAA.

THIS IS PAGE 19 OF 37 - PLEASE READ ALL PAGES

C. In the event the Medical Panel finds that a plaintiff or claimant is not entitled to payment under this Second MDL Program, a \$250 payment to defray costs paid for the medical records or assembly of same by the attorney for the plaintiff or the attorney for the claimant shall be paid from the administrative fund pursuant to Section 16B. It is understood that the only records required to be submitted to qualify for the \$250 reimbursement is a single medical or pharmacy prescription record indicating Propulsid use and a medical condition or injury which the claimant has attributed to Propulsid in Section 5A. All Orders or Minute Entries previously made or hereafter to be made by the MDL Court respecting the medical records needed to satisfy this requirement will control this Second MDL Program. This aspect of the Second MDL Program and the payment described are only for the benefit of actual Propulsid users.

6. PAYMENTS BY CATEGORY

A. Once the Medical Panel has determined that a person is eligible for payment and has identified the category, the Special Master shall decide what sum shall be awarded. In so deciding, the Special Master shall give consideration to those factors relevant to the payment of damages for the particular person under commonly accepted rights of recovery.

B. It is not possible to determine what payment will be made to any plaintiff or claimant until: (1) the Medical Panel has made its determinations of eligibility and, if eligible, the category of eligibility and (2) the Special Master has determined the amount to be paid. The final amount of these payments will not be determinable until the claims of all who enroll in this Program have been decided.

C. The Special Master is not to consider the amount of the settlement fund or the exhaustion of that fund as a limitation in making any award. In the event the total sums to be awarded to those persons found eligible under the Second MDL Program exceed the total sum available in the settlement fund, the awards shall be reduced and paid on a pro rata basis.

D. All relevant liens shall have been resolved before any payments are made under this Second MDL Program.

E. The parties will explore whether it is feasible to make a partial payment of a sum awarded to a plaintiff or claimant in advance of the final determination of the total sums to be awarded to all plaintiffs and claimants and the timing of release and indemnity agreement. If such a payment is made it will be recognized as a partial, not final payment, all subject to Section 6(B).

7. MEDICAL PANEL

A plaintiff or claimant shall have 120 days from the date of service by the PSC/SLC of notice that the Second MDL Program's minimum enrollment levels have been reached, or 120 days from the date a plaintiff or claimant serves an Enrollment Form, whichever is later, to serve a Claim Form. In extraordinary circumstances in cases where the attorney for plaintiffs or claimants has more than 100 such clients and has not submitted all the Claim Forms in a timely manner, the Special Master may grant a reasonable extension of time to complete submission of

THIS IS PAGE 20 OF 37 - PLEASE READ ALL PAGES

the remaining Claim Forms. If a plaintiff or claimant fails to submit the required medical records within 60 days after he or she has completed the claim form described in Section 5(A), that person's claim shall be dismissed with prejudice. No further action is to be taken on it and no litigation may be commenced or maintained to attempt to pursue that claim. However, if a plaintiff or claimant has made a good faith effort to secure records, then the period will be extended for 60 days, upon application to the Special Master. If the Special Master has determined that a good faith effort has been made to obtain the medical records, but they are still not available, the Panel may review the records available, but the possible recovery must still meet the requirements of the guidelines. If a plaintiff or claimant fails to submit the required medical records within the 60 day extension and the Special Master has determined that the plaintiff or claimant has not made a good faith effort to secure records, that person's claim shall be dismissed with prejudice. No further action is to be taken on it and no litigation may be commenced or maintained to attempt to pursue that claim. Once the required medical records have been received in the medical records depository, they shall be given to the Medical Panel together with the claim forms so that the Panel can decide whether the claim is eligible for payment.

8. ADMINISTRATION

The parties intend that the administration of this Second MDL Program shall be conducted in a manner designed to expedite medical records collections, the analysis of claims and the determination whether they qualify for acceptance or rejection.

9. MDL ASSESSMENT

A. This Second MDL Program is MDL 1355 work product, originally developed and agreed upon through court-ordered negotiations between Janssen, L.P. and the Plaintiffs' Steering Committee in MDL 1355. The use of this Second MDL Program for settlement purposes shall constitute consent by the plaintiff or a claimant under a tolling agreement to pay 6% of the gross amount of any award issued by the Special Master. This is pursuant to the common benefit trust fund to be established by a Pretrial Order in MDL 1355. This order will be available on the court's website, <http://propulsid.laed.uscourts.gov>.

10. NO ADMISSION OF LIABILITY

Neither Janssen's agreement to, nor participation in, this Second MDL Program constitutes an admission of liability to any person or other entity by Janssen, L.P. or any corporate entity or person related to it, e.g., Johnson & Johnson, Janssen Research Foundation, Janssen Pharmaceutica, N.V.

11. CONFIDENTIALITY

The amount and fact of settlements reached under this Second MDL Program are confidential, except as may be required by statute, court order, court rule, or the settlement approval process where court approval of a settlement is required by law in the relevant jurisdiction. Agreement to, and maintenance of, confidentiality are material terms of any settlement reached. An

THIS IS PAGE 21 OF 37 - PLEASE READ ALL PAGES

exemplar release will be jointly prepared by the parties. See Section 24 for additional provisions relating to confidentiality.

12. INFORMATION REQUIRED TO CONSUMMATE SETTLEMENT

A list of the information which must be provided to the attorneys for Janssen before a settlement check is delivered will be provided to the PSC.

13. PARTICIPATION

A. Death cases / cardiac arrest cases (Tiers I and II) - In these cases, the parties may provide within 60 days of the deadline for serving all required medical records confidential memoranda (simultaneously submitted at a date set by the two physician panel), explaining the party's contention as to a plaintiffs or claimant's qualification or non-qualification under the Second MDL Program and the category. Defendants shall have 60 additional days, and such further time as may be approved by the Special Master, to submit their memoranda if additional medical records must be subpoenaed after plaintiffs'/claimants' deadline for submitting all medical records has expired. Memoranda are limited to five (5) pages and exhibits attached may be abstracts or full documents not to exceed thirty (30) pages. There shall be no submission by either party of expert reports or affidavits in support of or in opposition to qualification or category.

B. Tier III - In these cases no memoranda of the type described in Section 13(A) shall be permitted and the Medical Panel shall rest its decision on the medical records submitted in accordance with Section 13(A). A one page summary may be submitted to point out the supporting documents and expedite medical review. There shall be no submission by either party of expert reports or affidavits in support of or in opposition to qualification or category.

C. In the event that the two medical panelists cannot agree on a plaintiffs or claimant's qualification or non-qualification and, if qualified, in which category, a third panel member will be selected on a rotating basis by the Special Master to cast the deciding vote. The rotation shall be a panelist appointed by the PSC, then a panelist appointed by the defense and so on in that order.

D. All decisions of the Medical Panel are final and not appealable (See Section 2(D)). All cases submitted to the Panel for decision will be decided within 45 days of submission to the Panel. In the event a third panelist is required, a decision will be forthcoming within 30 additional days. The deadlines may be extended by the Special Master upon showing of good cause. Thereafter, the Special Master may call for additional records such as birth, death, and/or marriage certificates, economic loss evidence (tax returns, pay stubs, benefits books income and support records) which must be furnished within 30 days of the request. The Special Master shall tentatively decide the level of payment to plaintiff claimant within 45 days of submission to him by the Medical Panel of its decision that a case qualifies for payment. This shall be subject to revision under Section 18(D). It shall remain confidential until a final determination is made by the Special Master. The final award by the Special Master is conclusive and non-appealable.

THIS IS PAGE 21 OF 37 - PLEASE READ ALL PAGES

THIS IS PAGE 22 OF 37 - PLEASE READ ALL PAGES

E. Except as is set forth in Section I(A)(B) defendants, by engaging in this Second MDL Program, waive and dismiss with prejudice all defenses of liability as to participating claimants such as statutes of limitation and repose, jurisdiction, venue, mitigation, comparative/contributory negligence, assumption of risk, independent intervening cause and products' liability, specific defenses such as state of the art, no safe alternative design; preemption, FDA and other regulatory approval, learned intermediary, etc. The defendants do not waive the defenses that the plaintiff or claimant was not exposed to Propulsid and that the claimed event was not caused or contributed to by use of Propulsid, as those requirements are necessary for any payment to be made pursuant to Tiers I, II and III in Exhibit A.

14. STANDARDS TO BE USED

A finding for eligibility to enter a defined category does not require findings of medical certainty but only findings that something is more probable than not. The following standards should be used by the Medical Panel or upon inquiries by it to the Special Master:

A. "But for" tests - whether harm (death, cardiac arrest or serious tachycardia ventricular arrhythmia) would more probably have occurred or not because of the user's ingestion of Propulsid.

B. Concurrent cause and substantial factor. Cause-in-fact is usually a "but for" inquiry which tests whether the harm would not have occurred "but for" the use of Propulsid, and the substantial factor inquiry is an alternative method of analysis used when two or more combined causes may be present. Thus, where there may be concurrent causes of an injury, the proper inquiry is whether the product in question was a substantial factor in bringing about the harm or injuries. A party's act maybe a substantial factor in bringing about the harm or injury when the harm would not have occurred without, the product's use.

C. The package literature identifies certain medications as contraindicated for use while Propulsid is being taken and identifies the presence of certain conditions as a contraindication for the use of Propulsid. The existence of such events in any claimant's case does not of itself entitle the claimant to a recovery nor deny a claimant a recovery.

D. Any legal interpretation of these standards may be referred by the Medical Panel to the Special Master on a case by case basis. The interpretation of the Special Master will be final and unappealable and will be rendered only in writing within 3 calendar days of the request.

15. MEMBERS OF MEDICAL PANELS

A. Six physicians, licensed in Louisiana and in good standing, or a lesser or greater number agreed to by the PSC, the SLC and Janssen, will be chosen 50% by Janssen and 50% by the PSC and SLC. They shall, if possible, be the physicians who already serve on the Medical Panel in the First MDL Program. The physicians must be recognized board certified cardiologists, electrophysiologists or internists who have had substantial training and substantial experience treating cardiac problems or physicians board certified in a specialty dedicated to the treatment of cardiovascular diseases or board certified physicians who have documented substantial

THIS IS PAGE 23 OF 37 - PLEASE READ ALL PAGES

training and experience treating cardiac problems. They may be active, semi-retired or retired. Each side will have veto over the other side's selection of any physician not currently on the MDL Medical Panel. A member of each physician group shall sit on a panel to determine category eligibility and non-eligibility. Once the members of the Medical Panel have been chosen and no veto as to their selection has been exercised, the parties shall have no ex parte contact with those members. In the event the parties agree to any training to be done with the members of the Medical Panel, that teaching will be done jointly.

B. If either party believes that a member of the Medical Panel is consistently disregarding the Second MDL Program's provisions respecting requirements for eligibility or non-eligibility, the PSC, SLC and defense counsel shall meet and confer to address the issue and, absent a resolution, either party may bring the matter to the attention of MDL Court which shall have the authority to remove the physician from the Medical Panel. The MDL Court will interview the challenged panelist in camera and, if necessary, remove the panelist. No counsel may be present at such hearing and the hearing and Order of the Court will be final and non-appealable and sealed in the record. That physician's replacement, if the MDL Court removes a physician, shall then be designated by the party who originally chose that physician. This provision is not intended to create an appeal system for occasional eligibility or non-eligibility decisions with which one party disagrees.

16. CLAIMANT ENTRANTS' BENEFITS

Any claimant electing to enter the Second MDL Program, in addition to potential entry into a category and level of payment, receives the following benefits:

- A. Waiver of defenses by the defendants to claimant's claim as provided in Section 13(E).
- B. Payment of \$250 pursuant to Section 5(C) to defray costs of obtaining the medical records described in Exhibit A, Section 2, if the Medical Panel finds, following a review of a sufficient amount of those records, that there is no entitlement to payment under the settlement fund.
- C. Establishment of a settlement process and fund.
- D. Expedited review and acceptance or rejection of claims.
- E. Evaluation of claimant's medical records and circumstances by at least (2) two qualified physicians without cost to claimant.

17. ADMINISTRATIVE FUND

- A. The following are examples of administrative expenses:
 - 1. Depository costs (including storage, document or electronic retention, equipment, paralegal and other employee salaries, rent and utilities).

THIS IS PAGE 24 OF 37 - PLEASE READ ALL PAGES

2. Payment of certain medical records pursuant to Section 5(C).
 3. Payment of fees to members of Medical Panels.
 4. Payment of fees to Special Master.
 5. Reimbursement of miscellaneous expenses agreed to by PSC, SLC and defendant.
 6. If the enrollments required to start the Program are reached, reimbursement of reasonable out of pocket expenses incurred by PSC and/or SLC in enrolling participants in the Program. The proposed expenses must be submitted to defense counsel in advance and agreed to within five days of their submission. If such agreement is not reached, the Special Master shall decide whether the expenses or any part of them shall be paid from The Administrative Fund.
- B. No administrative funds may be used to pay claims.
- C. Excess refunded to defendant.
- D. Defendant to supply \$3,000,000.00 after the Second MDL Program has become effective pursuant to Section 1(B).
- E. Account to be administered in New Orleans by financial institution of defendants' selection with interest accrual on balances. Periodic reports should be made to the Court of the interest earned, distributions made, and other matters involving the status of administration. Interest on those payments to be added to the administrative fund. Interest (after payment of taxes) on the \$3,000,000.00 or any portion thereof shall be added, if needed, to the Administrative Fund to meet its obligations. If not needed, the balance of any principal and/or interest shall be returned to the defendants.
- F. All category claims to be determined within 3 months of records submission.
- G. PSC and Janssen agree to establish joint medical and other records depository at the present location of the First MDL Program depository in New Orleans to be maintained and managed by the Special Master and his staff. Salary to be agreed upon and paid by the fund.

18. SETTLEMENT FUND

- A. The Settlement Fund will be established pursuant to Section 3(E). If there are unused funds in the MDL Settlement Fund in the First MDL Program, they shall be included as part of this Second MDL Fund and shall serve as part of the defendants' obligation under Section 3 to make settlement payments.

THIS IS PAGE 25 OF 37 - PLEASE READ ALL PAGES

- B. Claims verification and payment milestones (to be detailed in documents submitted with Consent Order).
- C. Claims to be paid within an agreed time after verification compliance.
- D. Each claim to escrow a reserve and escrow paid if total claims do not exceed fund.
- E. If claims exceed amount in Settlement Fund, then the Fund will be distributed pro rata (based on claims value) after all claims have been processed.
- F. If there are excess funds left in the Settlement Fund after payment of all awards made by the Special Master, the funds, along with any interest thereon, shall be returned to the defendants.

Until such time as the Special Master shall have made an award pursuant to this Second MDL Program, the Settlement Fund remains the property of the defendants; for the benefit of Propulsid claimants, subject to distribution only pursuant to the terms of this Second MDL Program.

19. ATTORNEY FEES:

In addition to the 6% fee due to the PSC pursuant to Section 9, the PCS and SLC shall be entitled to an additional fee and the parties have agreed that the PSC/SLC may seek and recover such attorneys' fees and costs. It is agreed that the PSC's and SLC's work product and efforts to date have been responsible for developing and creating the Second MDL Program, and that the PSC's and SLC's future involvement in the administration of the Program will confer a substantial benefit on all of its participants. The parties recognize that *Sprague v. Ticonic Nat'l Bank*, 307 U.S. 161 (1939), *Mills v. Electric Auto-Lite Co.*, 396 U.S. 375, 393 (1970) and other well-established authority, permit the district court to grant such an award based upon its inherent powers of equity and that such award shall be paid separately and in addition to the assessment already authorized by the Court in PTO No. 16. Consistent with this jurisprudence, the defendants have agreed to pay and not contest any award for attorneys' fees and costs in the amount up to and including, \$4,000,000.00, but defendants will not pay any sum in excess of that amount. The PSC and SLC are required to petition for such an award and the amount and propriety of the same shall be determined by the court upon recommendation by the Special Master. The defendants will pay that award within 30 days of receipt of the Order of the MDL Court rendering that award. If a dispute arises thereafter as to division of the attorneys' fee award or challenges relating to payment of the attorneys' fees, the MDL Court, Judge Fallon, shall direct the PSC/SLC as to appropriate escrow (escrow depository to be selected by the PSC/SLC) of the fund, partial payment to entitled attorneys, and in the MDL Court's sole discretion, determine the appropriate division of fees, which decision shall be final and non-appealable. It is understood that once defendants deliver the fee check to the PSC/SLC, they have no further responsibility whatsoever for the payment of any legal fees to any firm, person or legal entity and that the MDL Court's fee order may not be reviewed pursuant to FRCP 60 or on any other basis.

THIS IS PAGE 25 OF 37 - PLEASE READ ALL PAGES

THIS IS PAGE 26 OF 37 - PLEASE READ ALL PAGES

20. SETTLEMENT WITH AN INDEPENDENT PARTY REQUIREMENT

The plaintiff or claimant must provide the amount of any settlement reached with an entity other than Janssen, the identity of the party with whom or with which the settlement has been reached and information about the pendency of any case or claim by him or her involving use of Propulsid.

21. IMPLEMENTATION OF THE PROGRAM

The PSC, SLC and the defendants will submit to the MDL Court within 30 days of the execution of this document a proposed Consent Order and other mutually satisfactory documents establishing the Second MDL Program and seeking approval of the MDL Court to have it administered by the Special Master and otherwise be subject to the jurisdiction of the MDL Court. The Court Order will incorporate the terms of this document and such additional matters as the Court may direct or the parties agree are necessary to the implementation and management of the Second MDL Program. The parties do not presently foresee that matters not addressed in this document but which are necessary for inclusion in a Consent Order cannot be resolved between them. The PSC/SLC shall have 180 days from the date of that Consent Order to secure the required number of written consents from counsel for plaintiffs and persons under tolling agreements, as set forth in Section 1, and to present them to counsel for the defendants. If the requirements set forth in Section 1 have not been satisfied within the 180 day minimum enrollment period, this agreement shall terminate and the Second MDL Program will not be implemented unless otherwise agreed by the parties.

To the Consent Order should be attached the Enrollment Form attached as Exhibit B to be signed by counsel for plaintiffs and counsel for tolling agreement claimants and the claim form to be signed by plaintiffs and tolling agreement claimants when they submit their medical records. In particular, language in the Consent Order will have to make clear that all plaintiffs and the tolling agreement claimants, i.e., persons not presently subject to the jurisdiction of the MDL Court, and the defendants accept the jurisdiction of the MDL Court and that the MDL Court is, by their consent: a) empowered to enter an order terminating plaintiffs' and claimants' rights to sue the defendants if they fail to submit the medical records within the time set forth in the term sheet or if the Medical Panel does not decide that they are entitled to compensation and, b) empowered to enter an order authorizing the Special Master to pay from the settlement fund any award that he makes in favor of such a plaintiff or claimant consistent with this agreement.

22. ADMINISTRATION OF THE PROGRAM

The parties will include in the Consent Order appropriate provisions for the management of the Second MDL Program including duties to be performed by the Special Master, proposed fee arrangement, for members of the Medical Panel, as well as how they should fulfill their duties, reports to the PSC, SLC and the defendants about claims submissions under the Second MDL Program and all other administrative matters designed to accomplish the purposes set forth in Section 8. All plaintiffs or claimants who participate in the Second MDL Program stipulate and

THIS IS PAGE 26 OF 37 - PLEASE READ ALL PAGES

THIS IS PAGE 27 OF 37 - PLEASE READ ALL PAGES

agree that the Second MDL Program is and will remain subject to the jurisdiction of the MDL Court until all proceedings under the Second MDL Program have been concluded.


23. MEDICAL PANEL REVIEW PROCEDURES.

The parties shall prepare a joint written protocol for the members of the Medical Panel to follow in the performance of their responsibilities. The protocol shall cover the administrative issues respecting the work of the Medical Panel, e.g., time limits for case reviews, adherence to the Settlement Requirements set forth in Exhibit A, etc.

24. PUBLIC STATEMENTS ABOUT THIS SETTLEMENT

The PSC, SLC and the defendants shall prepare a joint statement describing this settlement and the Second MDL Program established herein and shall agree upon the manner and timing of distribution. This shall be the only statement to be distributed except as the PSC, SLC and defendants may further agree. The plaintiffs and claimants and their counsel agree that they shall make no public statement. These conditions are material conditions to this agreement. This will not constitute a restriction on plaintiffs' or claimants' attorneys' communication with their clients about this matter except to the extent there is use of the media or any other public forum for that purpose. The contents of this term sheet shall not be made public by any party until the consent order described in Section 21 has been entered. See Section 11 for additional confidentiality requirements.

Executed in triplicate original on this the 15th day of December, 2005.



RUSS M. HERMAN, T.A. (La. Bar #6819)

LEONARD A. DAVIS, #14190

JAMES C. KLICK, #7451

HERMAN, MATHIS, CASEY, KITCHENS & GERBEL, LLP


820 O'Keefe Avenue

New Orleans, Louisiana 70113

Phone: (504) 581-4892; Fax: (504) 561-6024

MDL LIAISON COUNSEL FOR PLAINTIFFS

MDL STATE LIAISON COMMITTEE



RICHARD J. ARSENAULT

Louisiana Bar Roll #38041


Neblett, Beard & Arsenault

P.O. Box 1190


Alexandria, LA 71309-1190

Telephone: 318-487-9874

Facsimile: 318-561-2591


David Bernier
with permission


THIS IS PAGE 28 OF 37 - PLEASE READ ALL PAGES




DAWN M. BARRIOS (La. Bar No. 2821)
Barrios, Kingsdorf & Casteix
701 Poydras Street, Suite 3650
New Orleans, La. 70139
Phone: 504.524.3300
Fax: 504.524.3313
barrios@bkc-law.com



JAMES T. CAPRETZ *with permission*
Capretz & Associates
5000 Birch Street
Suite 2500
Newport Beach, CA 92660
Telephone: 949-724-3000
Facsimile: 949-757-2635



BARRY M. HILL
Hill, Toriseva & Williams, PLLC
89 12th Street
Wheeling, WV 26003
Telephone: 304-233-4966
Facsimile: 304-233-4969



JAMES B. IRWIN, T.A. (La. Bar #7172)
QUENTIN F. URQUHART, JR. (La. Bar #14475)
KIM E. MOORE (La. Bar #8653)
MONIQUE M. GARSAUD (La. Bar #25393)
IRWIN FRITCHIE URQUHART & MOORE, LLC
400 Poydras Street, Suite 2700
New Orleans, Louisiana 70130
Phone: (504) 310-2100
Fax: (504) 310-2101
LIAISON COUNSEL FOR DEFENDANTS
JANSSEN, L.P. AND JOHNSON & JOHNSON

THIS IS PAGE 29 OF 37 - PLEASE READ ALL PAGES

DRINKER BIDDLE & REATH LLP
THOMAS F. CAMPION
SUSAN M. SHARKO
500 Campus Drive
Florham Park, NJ 07932-1047
Phone: (973) 549-7300
Fax: (973) 360-9831

- and -

DRINKER BIDDLE & REATH LLP
CHARLES F. PREUSS
DONALD F. ZIMMER, JR.
50 Fremont Street, 20th Floor
San Francisco, CA 94105-2235
Phone: (415) 591-7500
Fax: (415) 591-7510
CO-LEAD COUNSEL FOR DEFENDANTS,
JANSSEN, L.P. AND JOHNSON & JOHNSON

THIS IS PAGE 29 OF 37 - PLEASE READ ALL PAGES

THIS IS PAGE 30 OF 37 - PLEASE READ ALL PAGES

EXHIBIT A

SETTLEMENT REQUIREMENTS APPLICABLE TO ALL CASES

1. **FACTUAL REQUIREMENTS.** There must be credible evidence from the medical records that each of the following is more likely than not:

A. **EVENT** - The plaintiff or the plaintiffs decedent (hereinafter referred to jointly as the "person"), must have had an event. An event is defined as death, cardiac arrest or primary tachycardic ventricular arrhythmia. Primary tachycardic ventricular arrhythmia is limited, to primary, sustained ventricular tachycardia, ventricular fibrillation or torsades de pointes.

Primary is further defined as a symptomatic ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation) that occurs in the absence of a concurrently documented causative factor that precipitated the arrhythmia, including, but not limited to, acute myocardial infarction, active myocardial ischemia and decompensated congestive heart failure. Conditions such as hypokalemia or hypomagnesaemia documented at the time of the arrhythmia may be considered by the Medical Panel to be causative factors.

Sustained is further defined as continuous ventricular tachycardia 1) of at least 10 seconds duration, or 2) requiring termination through therapeutic intervention by precordial thump, electrical cardioversion or medication, or 3) with associated symptoms of hemodynamic deterioration such as syncope, presyncope (distinct feeling of impending loss of consciousness which does not eventuate) or shock. Neither dizziness nor lightheadedness is considered an associated symptom, nor is chest pain which precedes the arrhythmic event.

B. **INGESTION**- The person must have ingested Propulsid within 72 hours of the event or, in the case of death, within 72 hours of the arrhythmia that directly resulted in the subsequent death.

2. **MEDICAL RECORD REQUIREMENTS**

A. **For a person who was age 12 or older at the time of the event.** The person's relevant medical records as defined in subpart D below, immediately preceding the date of the event must be provided to the Medical Panel.

B. **For a person who was under age 12 at the time of the event.** The person's relevant medical records from birth through the date of the event must be provided to the Medical Panel.

C. **For all people.** The person's relevant medical records from the time of the event until death, or until 60 days before the time the case is submitted under The Program, whichever is applicable. These records are of particular importance in the evaluation process.

D. **Relevant records.** For the purposes of this Program, the following are a person's relevant medical records. Time periods are deemed appropriately modified where the person

THIS IS PAGE 31 OF 37 - PLEASE READ ALL PAGES

was less than twelve years of age at the time of the event. The PSC and J&J may agree to order supplemental records at the expense of the administrative expense fund:

- (1) **The one-year period before the event.** Full records for any kind of medical care in the one year preceding the event (doctor, hospital, pharmacy, ambulance, therapy, etc.).
- (2) **The three-year period before the event.**
 - (a) Full hospital records for hospitalizations.
 - (b) All electrocardiogram, holter monitor, and other cardiac monitoring or testing records for the three years before the event.
 - (c) Physician records from the person's primary care physician or physicians (if any), cardiologist or cardiologists (if any), gastroenterologists and/or pediatrician or pediatricians (if any).
 - (d) Prescription records for all prescribed medications.
- (3) **The ten-year period before the event.**
 - (a) Full hospital records where cardiac concerns are implicated.
 - (b) Full hospital records where GI concerns are implicated.
 - (c) Full EKG's.

2. SETTLEMENT CATEGORIES

TIER I: DEATH CASES

1. The medical records and other factual information are more consistent with a primary tachycardic ventricular arrhythmia being the cause of death than any other reasonable cause, and
2. Death would not have occurred but for decedent's use of Propulsid, or in those cases where there was more than one contributory cause to the death, Propulsid was a substantial factor as defined in Section 14(B), and
3. The autopsy findings, if any, are more consistent with a primary tachycardic ventricular arrhythmia being the cause of death than any other reasonable cause.

THIS IS PAGE 31 OF 37 - PLEASE READ ALL PAGES

THIS IS PAGE 32 OF 37 - PLEASE READ ALL PAGES

**TIER II: NONFATAL CARDIAC ARREST
LEVEL A**

1. No documented evidence of previous cardiac arrest, myocardial ischemia or myocardial infarction and no documentation that patient was at high risk for cardiac arrest before taking Propulsid, and
2. The arrest is more consistent with a primary tachycardic ventricular arrhythmia being the cause than any other reasonable cause, and
3. The arrest would not have occurred but for the patient's use of Propulsid, or in those cases where there was more than one contributory cause to the arrest, Propulsid was a substantial factor as defined in Section 14(B), and
4. The arrest was witnessed by a health care provider or required therapy such as CPR or defibrillation or was documented on an EKG or monitor.

LEVEL B

1. Some risk factors for cardiac arrest present, but no prior history of cardiac arrest and
2. The arrest is more consistent with a primary serious tachycardic ventricular arrhythmia being the cause than any other reasonable cause, and
3. The arrest would not have occurred but for the patient's use of Propulsid, or in those cases where there was more than one contributory cause to the arrest, Propulsid was a substantial factor as defined in Section 14(B), and
4. Medical Treatment was obtained following the arrest.

TIER III: PRIMARY TACHYCARDIC VENTRICULAR ARRHYTHMIA

1. The primary tachycardic ventricular arrhythmia must be documented in a rhythm strip, or there is documentation in the patient's medical records that the rhythm strip demonstrated the same, and
2. The primary tachycardic ventricular arrhythmia (including Torsades de Pointe) is more consistent with the patient's use of Propulsid than any other reasonable cause, and
3. The primary tachycardic, ventricular arrhythmia would not have occurred but for the patient's use, of Propulsid, or in those cases where there was more than one contributory cause to the primary tachycardic ventricular arrhythmia, Propulsid was a substantial factor as defined in Section 14 (B), and
4. Required medical attention in, the form off a hospital evaluation or ER visit for treatment of the arrhythmia.

THIS IS PAGE 1 OF 37 - PLEASE READ ALL PAGES

IN RE: PROPULSID® PRODUCTS LIABILITY LITIGATION

UNITED STATES DISTRICT COURT, EASTERN DISTRICT OF LOUISIANA

MDL NO. 1355

SECOND RESOLUTION PROGRAM

ENROLLMENT FORM

TO BE FILLED OUT BY COUNSEL FOR PLAINTIFFS AND CLAIMANTS


I.
AGREEMENT

The terms of the MDL 1355 Second Resolution Program are set forth in the December 19, 2005 Consent Order and in the Second MDL Term Sheet dated December 15, 2005 attached to that Order. Both of those documents are attached to this Enrollment Form and are made a part of this Enrollment Form. I certify that I have read and understand those documents.

I am the attorney for the plaintiffs identified in Attachment A. They are all the plaintiffs I represent whose cases are pending in federal courts. I am also the attorney for the tolling agreement claimants identified in Attachment A.

On behalf of the individuals on Attachment A, I hereby represent that I have communicated with and explained to them the contents of the Second MDL Term Sheet, the Consent Order and this Enrollment Form and have full authority from them to enroll them in this Second MDL Resolution Program. I further represent that I have explained to those individuals that: (1) enrollment in this Second MDL Resolution Program subjects them to the jurisdiction of the MDL Court until all proceedings under the Second MDL Resolution Program have been concluded, that they may not withdraw from the Second MDL Resolution Program, that they will be bound by its results whatever they may be, and that by entering the Second MDL Resolution Program they have surrendered all other rights and claims they may have respecting the use of Propulsid; (2) this Second MDL Resolution Program provides their sole and exclusive remedy for their claims other than as may be permitted under this Second MDL Resolution Program and serves as a release of those claims against Janssen, L.P., formerly known as Janssen Pharmaceutica Inc., Johnson & Johnson and all health care professionals, health care providers, health care facilities, pharmacies and other distributors of Propulsid®, and all of these individuals' and entities' parents and subsidiaries, affiliates, agents, attorneys, servants, employees, officers and directors and those who may have acted in concert with them, together with their respective insurers, and serves as a waiver of California Civil Code

THIS IS PAGE 1 OF 37 - PLEASE READ ALL PAGES



THIS IS PAGE 2 OF 37 - PLEASE READ ALL PAGES

Section 1542, if applicable, which provides that, "a general release does not extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor." (3) no claim may be advanced other than in this Resolution Program and that enrollment terminates any lawsuits which they have brought or could have brought; and (4) the potential benefits and risks to them if they enter the Second Resolution Program, including the fact that their claims shall be dismissed if they fail to file and serve a completed claim form and provide the required medical records within the time specified in Section 7 of the Term Sheet for this Second Resolution Program. I represent that those individuals have authorized me to represent that they accept all those conditions.

I hereby enroll in the Second MDL Resolution Program of all of the persons identified in Attachment A and consent and agree on their behalf and with their authorization to the terms of the Term Sheet. As required by the Term Sheet, I have executed individual Stipulations of Dismissal for any and all plaintiffs identified in Attachment A and submit it with this Enrollment Form.

ACCEPTED AND AGREED:

Dated: _____

[Plaintiffs'/Claimants' Attorney's Name]
[Law Firm Name]
[Address]
[City/Town, State, Zip Code]
[Area Code/Phone Number]
[Area Code/Fax Number]
[e-mail address]

**II.
INSTRUCTIONS**

A. To enroll in the Second Program, the following documents, which collectively comprise the complete enrollment form, must be prepared, dated, signed and properly served by June 17, 2006:

1. The within Enrollment Form;
2. Attachment A to the Enrollment Form (which lists identifying information about all Plaintiffs and Claimants enrolling in the Second MDL Program on this Enrollment Form – see template Attachment A);

THIS IS PAGE 2 OF 37 - PLEASE READ ALL PAGES

THIS IS PAGE 3 OF 37 - PLEASE READ ALL PAGES

3. For all Plaintiffs with active, filed Propulsid® lawsuits filed on or before November 15, 2005, an original, fully-executed Stipulation and Proposed Order of Dismissal With Prejudice Of Plaintiff's Entire Lawsuit and a Certificate of Service delivered to Lead Defense Counsel to be held in escrow; the Stipulation and Proposed Order of Dismissal With Prejudice and the Certificate of Service of Stipulation and Proposed Order of Dismissal must be in a format similar to the three template forms (Stipulation, Proposed Order of Dismissal and Certificate of Service of Stipulation and Proposed Order of Dismissal) collectively comprising Attachment B to this Enrollment Form;

4. Serve a complete set of the above-described documents along with an executed and dated Proof of Service in a format similar to the template Proof of Service of Enrollment Form at Attachment C hereto as follows:

(a) **the originals to the Office of the Program's Special Master:**

Special Master's Office
400 Poydras Street, Suite 2820
New Orleans, LA 70103
Phone: (504) 586-7995
Fax: (504) 586-1998

(b) **one copy to Lead Counsel for Defendants:**

Thomas F. Champion, Esq. and
Charles F. Preuss, Esq.
Drinker Biddle & Reath LLP
50 Fremont Street, 20th Floor
San Francisco, CA 94105-2235
Phone: (415) 591-7500
Fax: (415) 591-7510

(c) **one copy to Lead Counsel for Plaintiffs:**

Russ M. Herman, Esq. and
Leonard A. Davis, Esq.
Herman, Herman, Katz & Cotlar LLP
820 O'Keefe Avenue
New Orleans, LA 70113
Phone: (504) 581-4892
Fax: (504) 561-6024

THIS IS PAGE 3 OF 37 - PLEASE READ ALL PAGES

THIS IS PAGE 4 OF 37 - PLEASE READ ALL PAGES

B. Claim forms to identify the event for which compensation is sought under this Second MDL Resolution Program are required to be completed by each Enrollee. These forms are available on the Court's website at <http://propulsid.laed.uscourts.gov>. The Second Resolution Program will not become effective until the required number of persons have enrolled by the completion of these Enrollment Forms.

THIS IS PAGE 4 OF 37 - PLEASE READ ALL PAGES

THIS IS PAGE 6 OF 37 - PLEASE READ ALL PAGES

ATTACHMENT A TO ENROLLMENT FORM MDL 1355 RESOLUTION PROGRAM FOR ATTORNEY [LAW FIRM NAME]

Plaintiff/Claimant Name			Residence Address	Residence Telephone	Social Security No.	DOB	Plaintiff	Claimant	Achord Plaintiff
(Last)	(First)	(I.)							

Dated: _____

 [Plaintiffs'/Claimants' Attorney's Name]
 [Law Firm Name]
 [Address]
 [City/Town, State, Zip Code]
 [Area Code/Phone Number]
 [Area Code/Fax Number]
 [e-mail address]

THIS IS PAGE 7 OF 37 - PLEASE READ ALL PAGES

ATTACHMENT B TO ENROLLMENT FORM

UNITED STATES DISTRICT COURT

EASTERN DISTRICT OF LOUISIANA

	:	MDL NO. 1355
	:	
IN RE: PROPULSID	:	SECTION "L"
PRODUCTS LIABILITY LITIGATION	:	
	:	JUDGE FALLON
THIS DOCUMENT RELATES TO:	:	
[INSERT NAME OF CASE]	:	DOCKET NO. _____
	:	
.....	:	

ORDER OF DISMISSAL WITH PREJUDICE

Considering the foregoing Stipulation of Dismissal of this entire Lawsuit with Prejudice,

IT IS HEREBY ORDERED, ADJUDGED AND DECREED that all claims of plaintiffs, _____, individually and as representative of _____, against defendants Janssen, L.P., formerly known as Janssen Pharmaceutica Inc., and Johnson & Johnson and any other named defendants be dismissed in their entirety with prejudice, each party to bear its own costs.

Dated: _____, 2006

UNITED STATES DISTRICT JUDGE

THIS IS PAGE 8 OF 37 - PLEASE READ ALL PAGES

ATTACHMENT B TO ENROLLMENT FORM

UNITED STATES DISTRICT COURT

EASTERN DISTRICT OF LOUISIANA

	:	MDL NO. 1355
	:	
IN RE: PROPULSID	:	SECTION "L"
PRODUCTS LIABILITY LITIGATION	:	
	:	JUDGE FALLON
THIS DOCUMENT RELATES TO:	:	
[INSERT CASE NAME]	:	DOCKET NO. ____
_____	:	
.....	:	

STIPULATION OF DISMISSAL WITH PREJUDICE

Pursuant to Federal Rule of Civil Procedure 41(a), the undersigned counsel hereby stipulate that all claims of plaintiffs, _____, individually and as representative of _____, against defendants Janssen, L.P., formerly Janssen Pharmaceutica Inc., and Johnson & Johnson and any other named defendants be dismissed in their entirety with prejudice, each party to bear its own costs.

THIS IS PAGE 9 OF 37 - PLEASE READ ALL PAGES

[Attorney for Plaintiff]
[Firm Name, Address and Telephone]

JAMES B. IRWIN, T.A. (#7172)
MONIQUE M. GARSAUD (#25393)
Irwin Fritchie Urquhart & Moore LLE
400 Poydras Street, Suite 2700
New Orleans, LA 70130
Telephone: (504) 310-2100
LIAISON COUNSEL FOR
DEFENDANTS

[Co-Counsel for Plaintiff]
[Firm Name, Address and Telephone]

DRINKER BIDDLE & REATH LLP
THOMAS F. CAMPION
SUSAN M. SHARKO
500 Campus Drive
Florham Park, NJ 07932-1047
Telephone: (973) 549-7300

and

DRINKER BIDDLE & REATH LLP
CHARLES F. PREUSS
DONALD F. ZIMMER, JR.
50 Fremont Street, 20th Floor
San Francisco, CA 94105-2235
CO-LEAD COUNSEL FOR
DEFENDANTS

THIS IS PAGE 10 OF 37 - PLEASE READ ALL PAGES

ATTACHMENT C TO SECOND MDL PROGRAM ENROLLMENT FORM

CERTIFICATE OF SERVICE OF ENROLLMENT FORM

I, _____, declare that:

I am at least 18 years of age, and not a party to the above-entitled action. My business address is _____, Telephone: _____

On _____, I caused to be served the following document(s):

[LIST TITLE OF ENROLLMENT FORM THAT INCLUDES NAME OF LAW FIRM WHOSE CLIENTS ARE BEING ENROLLED AND LIST TITLES OF EACH DOCUMENT BEING SERVED WITH THE LAW FIRM'S ENROLLMENT FORM]

by enclosing a true copy of (each of) said document(s) in (an) envelope(s), addressed as follows:

- BY MAIL: I am readily familiar with the business' practice for collection and processing of correspondence for mailing with the United States Postal Service. I know that the correspondence is deposed with the United States Postal Service on the same day this declaration was executed in the ordinary course of business. I know that the envelope was sealed, and with postage thereon fully prepaid, placed for collection and mailing on this date, following ordinary business practices, in the United States mail at [City and State].
- BY PERSONAL SERVICE: I caused such envelopes to be delivered by a messenger service by hand to the address(es) listed below:
- BY OVERNIGHT DELIVERY: I enclosed a true copy of said document(s) in a Federal Express envelope, addressed as follows:
-

Special Master's Office
400 Poydras Street, Suite 2820
New Orleans, LA 70130
Telephone: (504) 586-7995
Facsimile: (504) 586-1998

Thomas F. Campion, Esq. AND
Charles F. Preuss, Esq.
DRINKER BIDDLE & REATH LLP
50 Fremont Street, 20th Fl.
San Francisco, CA 94105
Telephone: (415) 591-7500
Facsimile: (415) 591-7510

Russ M. Herman, Esq. AND
Leonard A. Davis, Esq.
Herman Herman Katz & Cotlar LLP
820 O'Keefe Avenue
New Orleans, LA 70113
Telephone: (504) 581-4892
Facsimile: (504) 561-6024

CERTIFICATE OF SERVICE

THIS IS PAGE 10 OF 37 - PLEASE READ ALL PAGES

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

THIS IS PAGE 11 OF 37 - PLEASE READ ALL PAGES

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

I declare under penalty of perjury under the laws of the State of [insert State of service] that the above is true and correct.

Executed on [Date] at [City and State].

[Name] _____

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA

IN RE: PROPULSID PRODUCTS	:	MDL NO. 1355
LIABILITY LITIGATION	:	
	:	SECTION: L
THIS DOCUMENT RELATES TO	:	
(All Plaintiffs, Enrollees, and Cases in the	:	
Second MDL Resolution Program)	:	JUDGE FALLON

**AFFIDAVIT OF PATRICK A. JUNEAU IN SUPPORT OF
DEFENDANTS' MOTION FOR AN ORDER TO TERMINATE THE CLAIMS OF
ALL ENROLLEES IN THE SECOND MDL RESOLUTION PROGRAM AND TO
AUTHORIZE RETURN TO THE DEFENDANTS THE BALANCE OF THE
SETTLEMENT FUND AND ADMINISTRATIVE FUND AFTER ALL
PAYMENTS DUE THEREUNDER HAVE BEEN MADE**

STATE OF LOUISIANA

PARISH OF LAFAYETTE


Patrick A. Juneau, having been duly sworn according to his oath, deposes and says:

1. I am the Court-appointed Special Master for both the First and Second MDL Resolution Programs and am authorized by this Court to exercise my rights and responsibilities as set forth in the Term Sheets for both Programs. I am familiar with the course of litigation in this matter and if called upon as a witness, could and would testify to the following facts relating to the Second MDL Resolution Program based upon my own personal knowledge.
2. The Special Master's Office collected and tracked the receipt of the enrollees' forms and sent to their counsel notices of delinquent and/or deficient submissions, as appropriate. The Special Master's Office additionally notified counsel for all enrollees of the enrollment status of each enrollee (whether each had been

disqualified and the reason(s) for that determination, with the opportunity to challenge that disqualification or seek reconsideration of same, whether each had been qualified and how each had been qualified – whether as a wrongful death plaintiff, a personal injury plaintiff or a tolling claimant). The Special Master’s Office regularly shared with the parties data updates regarding enrollment and the receipt of claim forms and medical records from enrollees.

3. As the Special Master’s Office received submissions from enrollees and deemed them complete for review, we forwarded the claim forms and medical records to a three-physician panel for review and eligibility determinations. For the remaining balance of submissions that were not deemed eligible for awards, claimants with sufficient records were entitled to payments to defray the costs of obtaining medical records required for participation in the Program (medical records reimbursements) in accordance with the Term Sheet. The Special Master’s Office processed and paid medical records reimbursements to a large number of enrollees in the Second MDL Resolution Program. All enrollees who received awards or medical records reimbursements have had their claims fully processed.
4. Some enrollees failed to submit claim forms. Some enrollees failed to submit medical records. Some enrollees failed to submit the necessary records to qualify them for medical records reimbursements. Each was given notice of these deficiencies, with the ability to cure them, and their claims were fully processed according to the requirements of the Term Sheet for the Second MDL Resolution Program.

5. All claims have been processed and finalized in the Second MDL Resolution Program, and it is appropriate now to terminate the Second MDL Resolution Program and the claims of all enrollees in the Second MDL Resolution Program.



PATRICK A. JUNEAU

Sworn to before me and subscribed
in my presence this 14th day of
September, 2012.



Notary Public

Name Printed: Felicia Guidry

Bar/Notary No. 065233

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA**

IN RE: PROPULSID PRODUCTS : **MDL NO. 1355**
LIABILITY LITIGATION :
: **SECTION: L**
THIS DOCUMENT RELATES TO :
(All Plaintiffs, Enrollees, and Cases in the :
Second MDL Resolution Program) : **JUDGE FALLON**

NOTICE OF HEARING

IT IS HEREBY ORDERED that a hearing on Defendants' Motion for an Order to Terminate the Claims of All Enrollees in the Second MDL Resolution Program and to Authorize Return to the Defendants the Balance of the Settlement Fund and Administrative Fund After All Payments Due Thereunder Have Been Made is set for the 3rd day of October, 2012, at 9:00 o'clock a.m.

New Orleans, Louisiana, this _____ day of _____, 2012.

UNITED STATES DISTRICT JUDGE

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA**

IN RE: PROPULSID PRODUCTS	:	MDL NO. 1355
LIABILITY LITIGATION	:	
	:	SECTION: L
THIS DOCUMENT RELATES TO	:	
(All Plaintiffs, Enrollees, and Cases in the	:	
Second MDL Resolution Program)	:	JUDGE FALLON

**ORDER TERMINATING THE CLAIMS OF ALL ENROLLEES
IN THE SECOND MDL RESOLUTION PROGRAM AND AUTHORIZING
RETURN TO THE DEFENDANTS THE BALANCE OF
THE SETTLEMENT FUND AND ADMINISTRATIVE FUND
AFTER ALL PAYMENTS DUE THEREUNDER HAVE BEEN MADE**

THIS CAUSE came on the Defendants’ Motion for an Order to Terminate the Claims of All Enrollees in the Second MDL Resolution Program and to Authorize Return to the Defendants the Balance of the Settlement Fund and Administrative Fund After All Payments Due Thereunder Have Been Made;

The Court, having considered the Motion and any response from the plaintiffs, finds that the Motion is well taken and should be and is hereby GRANTED.

IT IS THEREFORE ORDERED AND ADJUDGED that:

The claims and cases of the plaintiffs and other enrollees in the Second MDL Resolution Program listed on Exhibit D to the Quirk Affidavit are hereby terminated from the Second MDL Resolution Program and dismissed with prejudice as to all remaining defendants in this litigation.

IT IS FURTHER ORDERED AND ADJUDGED that:

The Second MDL Resolution Program is hereby completed and terminated.

IT IS FURTHER ORDERED AND ADJUDGED that:

All enrollees, claimants and plaintiffs in the Second MDL Resolution Program are forever barred from bringing any further claim against any defendant with respect to Propulsid® use.

IT IS FURTHER ORDERED AND ADJUDGED that:

The balance of the Settlement Fund and Administrative Fund, after all payments due thereunder are paid, be promptly returned to Defendants, Johnson & Johnson and Janssen Pharmaceuticals, Inc.

New Orleans, Louisiana, this _____ day of October, 2012.

UNITED STATES DISTRICT JUDGE